Insights - The private pharmaceutical company Eddingpharm will pay Amarin Corp (AMRN) $15 million for rights to develop and commercialize Amarin’s prescription-grade fish oil pill, Vascepa, in China, Hong … Continue Reading
Read NowInsights - Xencor, Inc (XNCR) priced an equity financing on Wednesday morning, selling 7.5 million shares of common stock at $14.25 for gross proceeds of $106 million. … Continue Reading
Read NowInsights - Healthcare investors will be well-aware of Valeant's (VRX) $10 billion acquisition of Salix Pharmaceuticals (SLXP), announced over the weekend, but Monday morning has already been crammed full of biotech dealflow. Here's a quick recap.
Read NowInsights - A draft of the 21st Century Cures Act carries serious implications for biopharma. Longer exclusivity, a faster approval process, and even the chance to SELL some exclusivity for certain products.
Read NowInsights - VBL Therapeutics (VBLT) and Celsus Therapeutics (CLTX) each announced disappointing Phase 2 results for their drug candidates in inflammatory indications.
Read NowInsights - In healthcare and pharmaceutical news this week, famed predictor of the subprime mortgage crisis and hedge fund manager Kyle Bass has taken aim at the … Continue Reading
Read NowInsights - Genzyme (of Sanofi [SNY]) announced on Wednesday a collaboration with the private gene therapy company Voyager Therapeutics.
Read Now
